US Government As Represented by the Secretary of the Army

USA As Represented by Secretary of the Navy

Mark A Guelta

Hugh R Carlon

Steven P Harvey

Bernard V Gerber

Melissa M Dixon

Leslie R McMahon

Sue Y Bae

Saumil S Shah

The invention comprises isolated, mutant, non-wild-type organophosphorus acid anhydrolase (OPAA) enzymes having two site mutations, methods of production, and methods of use to effectively degrade cylcosarin (GF) (cyclohexyl methylphosphonofluoridate) with greater catalytic efficiency than the wild-type OPAA.

Mutant OPAA enzymes with increased catalytic efficiency on cyclosarin

The invention is directed toward mutant, non-wild-type organophosphorus acid anhydrolases (OPPAs) having three or more site mutations, methods of production, kits and methods of use to effectively degrade toxic V-agent type chemical compounds such as VX, VR, CVX, and VM.

Mutant organophosphorus acid anhydrolase enzymes having increased catalytic efficiency on V-agents

The invention is directed toward mutant, non-wild-type organophosphorus acid anhydrolase enzymes having three site mutations, methods of production, and methods of use to effectively degrade toxic organophosphorus compounds, most preferably GP (2, 2'-dimethylcyclopentyl methylphosphonofluoridate).

Mutant OPAA enzyme with increased catalytic efficiency on GP

The invention is directed toward mutant, non-wild-type organophosphorus acid anhydrolase enzymes having three site mutations, methods of production, and methods of use to effectively degrade toxic organophosphorus compounds, most preferably GP (2,2'-dimethylcyclopentyl methylphosphonofluoridate).

Mutant OPAA enzyme with increased catalytic efficiency on organophosphorus compound GP

Disclosed herein are non-wild-type organophosphorus acid anhydrolases having two site mutations, methods of production, and methods of use to effectively degrade toxic chemicals such as ((RS)-Propan-2-yl methylphosphonofluoridate) (Sarin) and other organophosphorus compounds.

Mutant organophosphorus acid anhydrolases and uses thereof

Disclosed herein are non-wild-type organophosphorus acid anhydrolases having three site mutations, methods of production, and methods of use to effectively degrade toxic chemicals such as((RS)-Propan-2-yl methylphosphonofluoridate)(Sarin) and other organophosphorus compounds. Also provided are organophosphorus acid anhydrolase mutants capable of degrading Sarin with distinct selective stereospecificity preferences differing from the wild-type organophosphorus acid anhydrolase

Mutant organophosphorus acid anhydrolase enzymes with stereospecificity on Sarin enantiomers and uses thereof

The invention comprises isolated, mutant, non-wild-type organophosphorus acid anhydrolase (OPAA) enzymes having three site mutations, methods of production, and methods of use to effectively degrade organophosphorus compound EA1356 (2-methylcyclohexyl methylphosphonofluoridate) with greater catalytic efficiency than the wild-type OPAA enzyme.

Mutant OPAA enzymes with increased catalytic efficiency on organophosphorus compound EA1356

This invention is directed toward a non-wild-type organophosphorus acid anhydrolase enzyme having two site mutations, method of production, and method of use to more effectively degrade toxic organophosphorus compounds and, in particular, toxic chemical GD (3,3-Dimethylbutan-2-ylmethylphosphonofluoridate), than the wild type organophosphorus acid anhydrolase.

OPAA FL&#x2014;a mutant enzyme with increased catalytic efficiency on organophosphorus compound GD

The invention is directed toward non-wild-type organophosphorus acid anhydrolases having three site mutations, method of production, and method of use to effectively degrade toxic chemical compounds such as (Ethyl({2-[bis(propan-2-yl)amino]ethyl}sulfanyl)(methyl)phosphinate ('VX').

Mutated organophosphorus acid anhydrolases and their uses thereof

The invention is directed toward non-wild-type organophosphorus acid anhydrolases having three site mutations, method of production, and method of use to effectively degrade toxic chemicals such as N,N-diethyl-2-(methyl-(2-methylpropoxy)phosphoryl)sulfanylethanamine) ('VR').

Provided are non-wild-type organophosphorus acid anhydrolases that are capable of degrading (ethyl {2-[bis(propan-2-yl)amino]ethyl}sulfanyl) (methyl)phosphinate and other V-agents. Particular embodiments include an organophosphorus acid anhydrolase including an amino acid substitution at position 212.

Non-wild-type organophosphorus acid anhydrolases for enzymatic decontamination

An improved process of passing an aerosol mixture through a filter. The asol mixture solely contains about 70 to 76% isostearic acid, about 6 to 7% isopalmatic acid, about 7 to 11% myristic acid, and about 4 to 5% palmitic acid.

Method for measuring filter efficiency

An improved method of testing a particulate filter. This is accomplished by assing a salt nuclei coated with isopropyl isostearate.

Method for measuring and testing the efficiency of gas mask filters

An improved process of passing an aerosol mixture through a filter. The asol mixture solely contains in percentage, by volume, of about:

Method of measuring the efficiency of gas mask filters using non-toxic

An improved method of testing a particulate filter. This is accomplished by assing a salt nuclei coated with a mixture containing isostearic acid, isopalmatic acid, myristic acid and palmitic acid through the filter to be tested.

Growing community of inventors

White Marsh, MD, United States of America

Mark A Guelta